Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Suffers $440K Loss in its First Month since Seeking Chapter 11 Protection


In the first month since it filed for Chapter 11 protection, Vermillion suffered a net loss of more than $440,000, according to documents filed with the US Bankruptcy Court in Delaware.

According to the documents filed last week, Vermillion posted a net loss $441,168 in April. As of April 30 it had cash and cash equivalents of $575,568, which included $568,930 in cash.

On March 31, the day after it filed for bankruptcy protection, the company had cash and cash equivalents of $613,917, including $610,214 in cash.

The company recorded no revenues in April. As of April 30, Vermillion's assets totaled $10.2 million, down from $10.3 million as of March 31, while its liabilities totaled $32.5 million in April, up from $32.1 million as of March 31, according to the document.

The disclosure was made as the Fremont, Calif.-based diagnostics firm tries to salvage its business pending a hearing on its Chapter 11 filing [see PM 04/02/09]. It is also the first portrait of the company's finances since it released its third-quarter earnings for 2008, citing receipts of $124,000 and a net loss of more than $14 million through the first nine months of last year. The company had assets of $7.15 million and liabilities of about $32 million at the time.

Most recently the company motioned for approval of an incentive bonus plan for its three directors. [see PM 04/30/09]. While the company said the plan calls for specific performance targets to be met before directors Gail Page, James Burns, and John Hamilton would receive any bonuses, the trustee overseeing the case and Quest Diagnostics, a Vermillion creditor, challenged the motion. Vermillion's bonus plan, they said, violates US bankruptcy codes [see PM 05/14/09].

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.